AU2019212638B2 - Fc variants with enhanced binding to FcRn and prolonged half-life - Google Patents

Fc variants with enhanced binding to FcRn and prolonged half-life Download PDF

Info

Publication number
AU2019212638B2
AU2019212638B2 AU2019212638A AU2019212638A AU2019212638B2 AU 2019212638 B2 AU2019212638 B2 AU 2019212638B2 AU 2019212638 A AU2019212638 A AU 2019212638A AU 2019212638 A AU2019212638 A AU 2019212638A AU 2019212638 B2 AU2019212638 B2 AU 2019212638B2
Authority
AU
Australia
Prior art keywords
fcrn
binding
binding polypeptide
domain
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019212638A
Other languages
English (en)
Other versions
AU2019212638A1 (en
Inventor
Brian MACKNESS
Huawei Qiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65520379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019212638(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2019212638A1 publication Critical patent/AU2019212638A1/en
Application granted granted Critical
Publication of AU2019212638B2 publication Critical patent/AU2019212638B2/en
Priority to AU2025204826A priority Critical patent/AU2025204826A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019212638A 2018-01-26 2019-01-25 Fc variants with enhanced binding to FcRn and prolonged half-life Active AU2019212638B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204826A AU2025204826A1 (en) 2018-01-26 2025-06-26 Fc variants with enhanced binding to FcRn and prolonged half-life

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
US62/622,468 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204826A Division AU2025204826A1 (en) 2018-01-26 2025-06-26 Fc variants with enhanced binding to FcRn and prolonged half-life

Publications (2)

Publication Number Publication Date
AU2019212638A1 AU2019212638A1 (en) 2020-09-17
AU2019212638B2 true AU2019212638B2 (en) 2025-04-03

Family

ID=65520379

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019212638A Active AU2019212638B2 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to FcRn and prolonged half-life
AU2025204826A Pending AU2025204826A1 (en) 2018-01-26 2025-06-26 Fc variants with enhanced binding to FcRn and prolonged half-life

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204826A Pending AU2025204826A1 (en) 2018-01-26 2025-06-26 Fc variants with enhanced binding to FcRn and prolonged half-life

Country Status (15)

Country Link
US (1) US20190263934A1 (enExample)
EP (1) EP3743441A1 (enExample)
JP (3) JP7399880B2 (enExample)
KR (2) KR20250008975A (enExample)
CN (3) CN119350481A (enExample)
AU (2) AU2019212638B2 (enExample)
BR (1) BR112020015006A2 (enExample)
CA (1) CA3089602A1 (enExample)
CO (1) CO2020010269A2 (enExample)
IL (2) IL318916A (enExample)
MX (2) MX2020007882A (enExample)
MY (1) MY203898A (enExample)
PH (1) PH12020551134A1 (enExample)
SG (1) SG11202006905YA (enExample)
WO (1) WO2019147973A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015006A2 (pt) * 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada
CN114466663B (zh) * 2019-07-25 2026-01-02 建新公司 以FcRn拮抗剂治疗抗体介导的障碍的方法
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
JP7832123B2 (ja) * 2020-05-11 2026-03-17 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
WO2022090469A2 (en) * 2020-10-29 2022-05-05 Formycon Ag Ace2 fusion proteins and uses thereof
TW202306584A (zh) 2021-05-27 2023-02-16 法商賽諾菲公司 具有對Fc受體之增強親和力及改良熱穩定性的Fc變體
WO2023021169A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
US20240409618A1 (en) * 2021-10-13 2024-12-12 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
JP2026513101A (ja) 2022-10-25 2026-04-23 アブリンクス エン．ヴェー． エフェクター機能が強化された糖鎖改変Ｆｃ変異ポリペプチド
TW202432602A (zh) 2022-12-05 2024-08-16 法商賽諾菲公司 運鐵蛋白受體結合蛋白
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
TW202619716A (zh) 2024-07-23 2026-05-16 法商賽諾菲公司 Ｃｅｒｅｂｌｏｎ連接酶調節劑與ｂｃｍａ ｎｋ細胞銜接子的組合療法
WO2026125322A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125320A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125321A1 (en) 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
WO2014177459A2 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2018052556A1 (en) * 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
CA2577133A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) * 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8775090B2 (en) * 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
ES2573642T3 (es) * 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
PT3215528T (pt) * 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
SG11201702550WA (en) * 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
BR112020015006A2 (pt) 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
US20150050269A1 (en) * 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2014177459A2 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
WO2018052556A1 (en) * 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W. F. D. ACQUA ET AL: "Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences", THE JOURNAL OF IMMUNOLOGY, vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171 - 5180 *

Also Published As

Publication number Publication date
CO2020010269A2 (es) 2020-12-10
CN111788221B (zh) 2026-02-13
MX2025009543A (es) 2025-09-02
IL276286A (en) 2020-09-30
TW201940512A (zh) 2019-10-16
JP2021511830A (ja) 2021-05-13
IL318916A (en) 2025-04-01
MY203898A (en) 2024-07-23
NZ767453A (en) 2025-03-28
CN119350481A (zh) 2025-01-24
JP2024026255A (ja) 2024-02-28
CN111788221A (zh) 2020-10-16
MX2020007882A (es) 2020-12-03
IL276286B2 (en) 2025-07-01
JP7399880B2 (ja) 2023-12-18
JP7860946B2 (ja) 2026-05-18
RU2020128177A (ru) 2022-02-28
CA3089602A1 (en) 2019-08-01
BR112020015006A2 (pt) 2020-12-29
KR20200115568A (ko) 2020-10-07
CN122145612A (zh) 2026-06-05
SG11202006905YA (en) 2020-08-28
KR20250008975A (ko) 2025-01-16
KR102748986B1 (ko) 2025-01-02
PH12020551134A1 (en) 2021-05-31
AU2025204826A1 (en) 2025-07-17
WO2019147973A1 (en) 2019-08-01
IL276286B1 (en) 2025-03-01
EP3743441A1 (en) 2020-12-02
JP2026021377A (ja) 2026-02-10
AU2019212638A1 (en) 2020-09-17
US20190263934A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
AU2025204826A1 (en) Fc variants with enhanced binding to FcRn and prolonged half-life
US20210024620A1 (en) Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
TWI902889B (zh) 與vegf-a及ang2結合之抗體及其使用方法
CA3183389A1 (en) Bispecific antibody and use thereof
AU2020358898B2 (en) Hybrid antibody
US20250376526A1 (en) Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
RU2795592C2 (ru) Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения
BR122024014725A2 (pt) Usos de um antagonista de fcrn no tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn, polipeptídeos isolados, e composições farmacêuticas compreendendo os mesmos
WO2025088546A1 (en) Fc domain variants with enhanced fc receptor binding
KR20250094703A (ko) 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
HK40086991A (en) Antibody that binds to vegf-a and ang2 and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)